Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 115,850 | 118,370 | 234,195 | 118,719 | 147,703 |
| Marketable Securities | 480,224 | 217,630 | 128,599 | 622,203 | 220,310 |
| Receivables | 308,455 | 234,210 | 231,072 | 90,975 | 97,730 |
| Inventories | 141,860 | 127,601 | 100,123 | 53,908 | 60,747 |
| TOTAL | $1,085,340 | $746,424 | $739,013 | $926,287 | $554,764 |
| Non-Current Assets | |||||
| PPE Net | 75,035 | 74,944 | 75,570 | 8,794 | 10,593 |
| Intangibles | 818,651 | 889,700 | 955,701 | 0 | 0 |
| Other Non-Current Assets | 84,451 | 22,202 | 71,227 | 169,348 | 14,567 |
| TOTAL | $978,137 | $986,846 | $1,102,498 | $178,142 | $25,160 |
| Total Assets | $2,063,477 | $1,733,270 | $1,841,511 | $1,104,429 | $579,924 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 13,334 | 89,419 | 397,228 |
| Accounts payable and accrued liabilities | 10,249 | 11,816 | 17,693 | 1,541 | 1,928 |
| Accrued Expenses | 128,851 | 100,678 | 99,762 | 24,441 | 20,483 |
| TOTAL | $139,100 | $112,494 | $130,789 | $117,147 | $421,385 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,505,798 | 1,499,248 | 1,492,766 | 787,255 | N/A |
| Deferred Revenues | N/A | N/A | N/A | 1,746 | 1,746 |
| Other Non-Current Liabilities | 54,758 | 37,720 | 48,158 | 544 | 3,466 |
| TOTAL | $1,560,556 | $1,536,968 | $1,540,924 | $790,329 | $7,492 |
| Total Liabilities | $1,699,656 | $1,649,462 | $1,671,713 | $907,476 | $428,877 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 123,153 | 126,825 | 135,367 | 137,704 | 135,276 |
| Common Shares | 123 | 127 | 135 | 138 | 135 |
| Retained earnings | 359,869 | 90,550 | 143,217 | -58,912 | -474,593 |
| Other shareholders' equity | 3,829 | -9,278 | -922 | -620 | 22 |
| TOTAL | $363,821 | $83,808 | $169,798 | $196,953 | $151,047 |
| Total Liabilities And Equity | $2,063,477 | $1,733,270 | $1,841,511 | $1,104,429 | $579,924 |